Introduction
============

Colorectal cancer (CRC) is a heterogeneous complex of diseases accompanied by the accumulation of distinctive genetic and epigenetic alterations. Despite more and more molecular pathways underlying CRC are identified during the last years, very few biomarkers can be used to predict survival accurately.[@b1-cmar-10-1365]--[@b3-cmar-10-1365] Prognostication mainly relies on stage at diagnosis and treatment.

With the identification of the microsatellite instability (MSI) phenotype and the corresponding longer patient survival, the host immune response, notably a greater lymphocytic reaction, has become a research hotspot in CRC.[@b4-cmar-10-1365],[@b5-cmar-10-1365] In addition, recent clinical results obtained with immune checkpoint blockade in metastatic CRC (mCRC) provide compelling evidence that spontaneous immunosurveillance and T cells play an important role in the control of CRC progression.[@b6-cmar-10-1365] However, the prognostic and predictive implications of tumor-infiltrating lymphocytes (TILs) in mCRC remain poorly understood.

Some evidence has shown that patients with high TILs at any stage generally have a better prognosis than those with low TIL disease; however, these analyses included patients with predominately nonmetastatic disease.[@b5-cmar-10-1365],[@b7-cmar-10-1365]--[@b10-cmar-10-1365] These studies were also restricted by the limited information on treatments and pathologic features. Finally, it remains to be determined whether the presence of TILs provides prognostic information independent of the established prognostic factors, such as treatment regimen, MSI and the number of metastasis sites involved; all these variables have been associated with prognosis and may confound each other in survival analysis.[@b11-cmar-10-1365],[@b12-cmar-10-1365]

In this study, we aimed to investigate the distribution and clinical relevance of TILs in the mCRC setting. Thus, we first assessed the relationship between TIL quantity and clinical outcome as well as clinicopathologic features in a large consecutive series of mCRC patients diagnosed and treated at a single institution to analyze the prognostic effect of baseline host antitumor immunity in this setting. Second, we also explored whether the prognostic value of TIL quantity differed with respect to metastatic status and metastasectomy, considering distant metastases are a major cause of death in patients with CRC.

Materials and methods
=====================

Study population
----------------

This study reviewed 2215 consecutive patients with CRC who underwent primary tumor resection at the Sun Yat-Sen University Cancer Center between 2009 and 2014. Eligibility criteria were pathologically confirmed CRC, synchronous distant metastasis at the time of diagnosis, no history of previous malignancies or concomitant primary cancer, no inflammatory bowel disease, no Lynch syndrome, availability of H&E-stained (HES) slides from primary tumor tissues as well as complete data on clinicopathological features (age, sex, tumor size, grade, and treatment regimen), and survival. A total of 332 patients newly diagnosed with stage IV CRC met these criteria and were included in the present study. Cancers located proximal to the splenic flexure were classified as right sided; left-sided cancers included tumors arising distal to the splenic flexure and sigmoid colon, or rectal cancers. The extent of tumor spread was determined using X-ray, CT, MRI, and/or PET preoperatively. Intraoperative findings also contributed to the determination of tumor involvement. CRC with 5 or fewer metastases was termed as oligometastatic CRC. This study was approved by the Ethics Committee of Sun Yat-Sen University Cancer Center, and written informed consent was obtained from all patients.

TILs
----

HES slides from primary tumor specimens for all patients were retrieved from the Institutional Pathology Archives. The extent of TILs was assessed by using a 4° scale and recorded as 0 (absent), 1+ (mild), 2+ (moderate), or 3+ (marked), as described in previous reports.[@b8-cmar-10-1365],[@b10-cmar-10-1365] In this method, all mononuclear cells, including lymphocytes and plasma cells are evaluated (granulocytes and polymorphonuclear leukocytes are excluded). Sections were defined as high TIL if scored 2 or 3 and as low TIL if scored 0 or 1. For technical reasons (e.g., low tumor area, poor staining technique, etc.), cases that could not be appropriately evaluated were designated as not evaluable. Where there was disagreement regarding TIL category between pathologists, joint reevaluation was performed to arrive at a consensus.

Immunohistochemistry and assessment of mismatch repair (MMR) status
-------------------------------------------------------------------

Immunohistochemistry for the 4 most common MMR proteins was performed with the standard Envision 2-step procedure, as described in the Supplementary materials.

Statistical analysis
--------------------

All statistical analyses were performed using SPSS version 20.0 (IBM Inc., Armonk, NY, USA) or Stata 12 (StataCorp LLC, College Station, TX, USA). Chi-squared test or Fisher's exact test was used to analyze the correlations between TIL infiltration and patients' clinicopathological features. Overall survival (OS) was defined as the time from the diagnosis of the cancer until any-cause death or to the last follow-up for cases that were alive. Kaplan--Meier curves and log-rank tests were performed to compare survival across groups of high TILs vs. low TILs. Unadjusted and multivariable Cox proportional hazards regression analyses were used to evaluate the association between TIL infiltration and clinical outcome as well as the corresponding hazard ratios and 95% CIs. Multivariable models included the following baseline variables: age, sex, lymph node status, primary tumor location, T-stage, histological grade, MMR status, previous therapy, adjuvant therapy, oligometastatic status, number of metastatic organs, and metastasectomy. A multivariate analysis using the Cox proportional hazards regression model was performed on all variables with *P*\<0.05 in a univariate analysis to determine the independent prognostic value of TILs for patient outcomes. The effect of TIL infiltration on survival outcomes was also estimated in subgroup analyses stratified by metastatic status. All the statistical tests were 2-sided and considered significant when *P* value ≤0.05.

Results
=======

Clinicopathological characteristics and association with TIL
------------------------------------------------------------

HES slides from primary tumor specimens were evaluable for 302 of the 332 included cases. No difference was observed in the study population (302 patients) and the non-assessable patients ([Table S1](#SD2-cmar-10-1365){ref-type="supplementary-material"}).

The median patient age was 58 years (range: 18--90 years), and 196 patients (64.9%) were male. The primary tumors were located in the rectum (65 patients, 21.5%) or the colon (233 patients, 77.2%). The majority of the patients had node-positive disease and 69 patients presented with a grade 3 tumor (22.8%). One hundred and ninety-seven (65.2%) patients had metastases confined to an organ, while 105 (34.8%) patients had metastatic sites spread over at least 2 organs. Metastasectomy was performed in 58 (19.2%) of these patients, whereas 244 (80.8%) had a palliative resection of the primary cancer. Among those patients, 74.8% received chemotherapy after surgery, and 20.5% received chemo/radiotherapy before surgery. Approximately 18.5% of the patients did not receive any systemic chemotherapy, and surgical resection was the only tumor-directed therapy.

Representative images of TIL evaluation results are shown in [Figure S1](#SD1-cmar-10-1365){ref-type="supplementary-material"}. One hundred and five patients were classified as high TIL; the remaining 197 were classified as low TIL. As presented in [Table 1](#t1-cmar-10-1365){ref-type="table"}, high TIL was significantly associated with the MMR deficiency (*P*=0.02) and tended to be more prominent in the absence of lymphatic invasion (*P*=0.06) or oligometastatic tumors (*P*=0.05). No correlation with other features, especially with the type of treatment, was observed.

Association of TILs with prognosis
----------------------------------

After a median follow-up of 27.7 months, a total of 172 (56.9%) deaths occurred. Those patients with a high TIL experienced a significantly better OS when compared with the low TIL group (HR, 0.67; 95% CI: 0.48--0.92; log-rank *P*=0.01). Kaplan--Meyer survival curves are represented in [Figure 1A](#f1-cmar-10-1365){ref-type="fig"}. Age at diagnosis, primary site, operation modality, lymph node status, oligometastatic status, number of metastatic organs, and adjuvant therapy were the other parameters associated with outcome.

Multivariable analysis confirmed that high TILs (HR, 0.62; 95% CI: 0.44--0.89, *P*=0.008) were associated with a statistically significant reduction in all-cause mortality ([Table 2](#t2-cmar-10-1365){ref-type="table"}).

Stratified analysis of the correlation between TILs and OS based on metastatic lesion
-------------------------------------------------------------------------------------

As distant metastases are a major cause of death in patients with CRC, we further evaluated whether TIL had a different prognostic impact in the group of patients stratified by metastatic lesion, including oligometastatic status, number of metastatic organs, and metastasectomy. Kaplan--Meyer survival curves in each subgroup according to TIL are represented in [Figure 1B--D](#f1-cmar-10-1365){ref-type="fig"}. TIL was associated with a major prognostic value in patients with non-oligometastatic disease (*P*=0.002), ≥2 metastatic organs (*P*=0.006), and non-metastasectomy (*P*=0.005). In contrast, in the cohort with oligometastatic disease (*P*=0.60), 1 metastatic organ (*P*=0.40), or metastasectomy (*P*=0.24), we did not detect any significant associations between OS and level of TILs. For visual purposes, forest plots for the independent prognostic effect of TIL adjusted by other parameters in each subgroup are reported in [Figure 2](#f2-cmar-10-1365){ref-type="fig"}.

The same results were obtained with a subgroup analysis, excluding patients who received chemo/radiotherapy before surgery ([Table S2](#SD3-cmar-10-1365){ref-type="supplementary-material"}).

Discussion
==========

To the best of our knowledge, this study is the first to present the prevalence and clinical relevance of TILs in the initial stage IV CRC setting, investigating a large series and consecutive patients diagnosed and treated at a single institution. We identified a significant association between increased TILs score and improved OS in this population, independent of other patient characteristics. Our report is also unique in that we analyzed the influence of metastatic status and metastasectomy on the prognostic effects of immune infiltrates. We found that the level of TILs is only of prognostic benefit when metastases are extensive or curative-intent surgery cannot be achieved. Our data strongly indicate the clinical relevance of antitumor immunity in stage IV CRC.

Recent cumulative immunosurveillance data suggested that a dynamic and complex interaction exists between immune cells and tumor cells, and this interaction tightly controls tumor progression.[@b13-cmar-10-1365] The presence of abundant TILs is associated with a favorable prognosis for various human solid tumors, including CRC.[@b5-cmar-10-1365],[@b7-cmar-10-1365]--[@b10-cmar-10-1365],[@b14-cmar-10-1365]--[@b16-cmar-10-1365] However, there are very few reported data on the survival impact and clinical relevance of TILs in patients with mCRC. Here, we showed that the presence of TILs is strongly associated with improved prognosis. Of note, node-negative tumors tend to have more TILs than node-positive tumors, which is in line with the observation in breast cancer and melanoma.[@b17-cmar-10-1365],[@b18-cmar-10-1365] Interestingly, for the first time, we also found that the amount of TILs in oligometastatic CRC tends to be much higher (40.7% in our series) than that found in the more invasive subtype (roughly 29.9%). These data suggest that TILs in mCRC represents a potent stimulator of the immune system, and the alterations in overall immune function may underlie risk for tumor spread in mCRC patients.

Complete resection of metastatic lesions in selected patients substantially improves survival rates and long-term survival can be expected.[@b19-cmar-10-1365] Therefore, not surprisingly, patients in the radical resection or oligometastases cohort showed a better prognosis in general. However, the heterogeneous prognostic effect of TILs according to oligometastatic status, metastatic site, and metastasectomy deserve further discussion. In contrast to the traditional immune tumor control hypothesis, one would expect that the effect of TIL infiltration on prognosis benefit could be maximized when tumor burden is small; our data indicate that TILs are of prognostic benefit only when metastases are extensive or when radical excision cannot be achieved. Nevertheless, the phenomenon is not completely surprising, especially if one considers that TILs are a robust predictive adjunct in invasive breast cancer, but their clinical role in ductal carcinoma in situ has not been observed.[@b20-cmar-10-1365],[@b21-cmar-10-1365] The absence of prognostic effect of TIL for limited metastasis represented by oligometastatic status suggests that immune aspects do not represent the key feature of this cancer type. Yet, little is known so far about the molecular basis for programmed polymetastatic or oligometastatic spread. It is reasonable to speculate that genetic properties of lesions with an oligometastatic phenotype were different from lesions "programmed" for polymetastatic dissemination.[@b22-cmar-10-1365] The potential difference in tumor biology may contribute to diversity in the immune microenvironment, including the severity of functional impairment of tumor-specific T cells and sensitivity of tumor cells to attack by cytotoxic T cells. Thereby, the heterogeneous prognostic effect of TILs can be expected. Besides, the multifaceted interplay between anti- or pro-tumoral leukocytes and mediators in the tumor microenvironment should not be ignored. Many studies indicate that the recruitment of immunosuppressive cells, such as immunoregulatory myeloid cells, regulatory T cells, T helper 17 cells, and regulatory B cells to the primary tumor site protects cancer cells from being killed by cytotoxic cells and this increases the probability of tumor cell survival and dissemination. Accordingly, a high content of immunosuppressive cells may point toward poor survival.[@b23-cmar-10-1365] However, the relative densities of specific subpopulations of these lymphoid cells are almost indistinguishable in H&E routine slides. Therefore, TILs evaluation seems premature, disregarding TILs evaluation in the setting of limited metastasis.

The finding that TILs can identify a subset of patients unamenable to curative-intent surgery with excellent outcome has several implications in patient stratification and precise treatment. Although a number of retrospective studies have suggested that primary tumor resection is safe and associated with better outcome in mCRC patients,[@b24-cmar-10-1365]--[@b27-cmar-10-1365] to date, there have been no effective factors to identify surrogates for palliative resection in the mCRC setting. Patient selection for palliative resection is only based on tumor dissemination, comorbidity, and performance status. In the present study, patients with a high TIL score presented a favorable outcome for extensive metastatic lesions. In other words, in the presence of adverse prognostic factors, a high lymphocytic infiltration could distinguish a group of patients to be good candidates to receive palliative resection. On the other hand, even in the presence of favorable prognostic factors, a low lymphocytic infiltration could distinguish a group of patients with very poor survival, who would not benefit from the palliative resection of primary tumor. Thus, TIL score could individualize more precise treatment strategies of mCRC and optimize cost-effectiveness ratio.

Although our study is considerably strengthened by the large sample size, detailed follow-up time and data on cancer treatment, it is not without limitations. In this study, cases were excluded if there was non-assessable archival material for full pathological analysis. However, the clinical features of the excluded patients did not differ significantly from those included in the study. In contrast to breast cancer, there is no current consensus for evaluating the level of TILs in CRC.[@b28-cmar-10-1365] Although our study provides a simple and readily available method of interpreting TILs using full-face HES sections, the methodology for assessment of TILs in CRC needs to be standardized in future, to make it practical for routine use.

Conclusion
==========

We provide, for the first time, a comprehensive evaluation of TILs in a large and well-characterized cohort of mCRC patients. Our analyses demonstrate that TILs have a strong prognostic effect in patients with mCRC, and metastatic status and metastasectomy should also be taken into account. This easy-to-collect information could be of great value in clinical decision making. Further studies characterizing the landscape and prognostic effect of TIL subpopulations are warranted and may provide more precise biologic significance of immune response in mCRC.

Supplementary materials
=======================

Immunohistochemistry and assessment of mismatch repair (MMR) status
-------------------------------------------------------------------

Briefly, after the specimens were dewaxed, hydrated, and washed, endogenous peroxidase was blocked (0.3% H~2~O~2~ for 10 min), and microwave antigen retrieval was performed in Tris-EDTA (pH 9.0). The slides were then incubated with blocking serum at room temperature for 30 min and with the primary antibody at 4°C overnight. The sections were serially rinsed, incubated with secondary antibodies, and visualized with diaminobenzidine following counterstaining with hematoxylin. The primary antibodies against the following proteins were used: MLH1 (1:50; Beijing Zhong Shan-Golden Bridge Biological Technology, Beijing, China), PMS2 (1:50; Beijing Zhong Shan-Golden Bridge Biological Technology, Beijing, China), MSH2 (1:50; Beijing Zhong Shan-Golden Bridge Biological Technology, Beijing, China), and MSH6 (1:50; Beijing Zhong Shan-Golden Bridge Biological Technology, Beijing, China). The PBS replaced the primary antibody as a negative control. And the known MMR-deficient colorectal carcinomas served as external negative controls. Stromal cells, non-neoplastic colonic mucosa, infiltrating lymphocytes, or the centers of lymphoid follicles were used as internal positive controls. Normal expression was defined as nuclear staining within tumor cells, while negative protein expression was defined as complete absence of nuclear staining within tumor cells with concurrent internal positive controls. Tumor with loss of MLH1/PMS2/MSH2/MSH6 protein as visualized by light microscopy was defined as MLH1/PMS2/MSH2/MSH6 negative. The procedure was routinely repeated if internal non-neoplastic tissues showed invalid negative staining. When discordance were found between the opinions of the two pathologists, agreement was reached by careful discussion.

###### 

Representative cancer specimens stained with H&E demonstrating examples with absent (**A**), mild (**B**), moderate (**C**), or marked (**D**), of tumor-infiltrating lymphocytes, respectively.

###### 

Baseline characteristics

  Variable                           Patients with evaluable TILs (*N*=302)   Patients with non-evaluable TILs (*N*=30)   *P*-value
  ---------------------------------- ---------------------------------------- ------------------------------------------- -----------
  Age (years)                                                                                                             
   \<65                              232 (76.8)                               24 (75.0)                                   0.69
   ≥65                               70 (30.2)                                6 (25.0)                                    
  Sex, No. (%)                                                                                                            
   Male                              196 (64.9)                               18 (60.0)                                   0.59
   Female                            106 (35.1)                               12 (40.0)                                   
  Histological grade (%)                                                                                                  
   Moderate/well differentiated      205 (67.9)                               21 (70.0)                                   0.94
   Poorly differentiated             69 (22.8)                                6 (20.0)                                    
   Other or missing                  28 (9.3)                                 3 (10.0)                                    
  Primary site (%)                                                                                                        
   Right-side colon                  90 (29.8)                                9 (30.0)                                    0.93
   Left-side colon                   143 (47.4)                               14 (46.7)                                   
   Rectum                            65 (21.5)                                7 (23.3)                                    
   Other or missing                  4 (1.3)                                  0 (0)                                       
  T-stage (depth of invasion) (%)                                                                                         
   T1--3                             185 (61.3)                               14 (46.7)                                   0.28
   T4                                112 (37.1)                               15 (50.0)                                   
   Tx                                5 (1.7)                                  1 (3.3)                                     
  N-stage (lymphatic invasion) (%)                                                                                        
   N0                                92 (30.5)                                12 (40.0)                                   0.17
   N+                                203 (67.2)                               16 (53.3)                                   
   Nx                                7 (2.3)                                  2 (6.7)                                     
  MMR status (%)                                                                                                          
   dMMR                              14 (4.6)                                 2 (6.7)                                     0.62
   pMMR                              288 (95.4)                               28 (93.3)                                   
  Previous therapy (%)                                                                                                    
   De novo metastatic disease        240 (79.5)                               20 (66.7)                                   0.11
   Previous (neo) adjuvant therapy   62 (20.5)                                10 (33.3)                                   
  Metastasectomy (%)                                                                                                      
   +                                 58 (19.2)                                9 (30.0)                                    0.16
   −                                 244 (80.8)                               21 (70.0)                                   
  No. of metastatic organs (%)                                                                                            
   1                                 197 (65.2)                               20 (66.7)                                   0.88
   ≥2                                105 (34.8)                               10 (33.3)                                   
  Adjuvant chemotherapy (%)                                                                                               
   Negative                          76 (25.2)                                6 (20.0)                                    0.53
   Positive                          226 (74.8)                               24 (80.0)                                   
  Oligometastatic status (%)                                                                                              
   Yes                               135 (44.7)                               12 (40.0)                                   0.62
   No                                167 (55.3)                               18 (60.0)                                   

**Note:** Data are presented as total number (%).

**Abbreviations:** dMMR, deficient mismatch repair; MMR, mismatch repair; pMMR, proficient mismatch repair; TILs, tumor-infiltrating lymphocytes.

###### 

Adjusted hazard ratio of TIL for overall survival in different colorectal cancer subtypes excluding patients who received chemo/radiotherapy before surgery

  Subgroup                   *N*   HR     95% CI       *P*-value
  -------------------------- ----- ------ ------------ -----------
  Metastasectomy                                       
   −                         194   0.58   0.38--0.89   0.01
   +                         46    0.86   0.28--2.65   0.80
   Oligometastatic           113   1.06   0.58--1.92   0.85
   No oligometastatic        127   0.58   0.34--0.97   0.04
  No. of metastatic organs                             
   1                         153   0.89   0.56--1.42   0.63
   ≥2                        87    0.39   0.20--0.78   0.008
   Overall                   240   0.61   0.41--0.90   0.01

**Abbreviations:** HR, hazard ratio; TILs, tumor-infiltrating lymphocytes.
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![Prognostic value of TIL.\
**Notes:** Estimated Kaplan--Meier curves of overall survival for all patients (**A**) and in patients grouped by TIL level and oligometastatic status (**B**), in patients grouped by TIL level and number of metastatic organs (**C**) and in patients grouped by TIL level and metastasectomy (**D**). All statistical tests were two-sided.\
**Abbreviations:** HR, hazard ratio; TIL, tumor-infiltrating lymphocyte.](cmar-10-1365Fig1){#f1-cmar-10-1365}

![Prognostic value of TILs and effect of metastatic status.\
**Notes:** Forest plots show the HR for high lymphocytic infiltration according to oligometastatic status, number of metastatic organs, and metastasectomy. These HRs were derived with a Cox regression model. Overall HRs were adjusted for other clinicopathological factors. The solid vertical line indicates an HR of 0.608, which is the value for all patients, and the dashed vertical line indicates an HR of 1.00, which is the null-hypothesis value.\
**Abbreviations:** HR, hazard ratio; TIL, tumor-infiltrating lymphocyte.](cmar-10-1365Fig2){#f2-cmar-10-1365}

###### 

Tumor characteristics stratified by T lymphocyte infiltration status

  N (%)                                                      
  ------------------------------- ------------- ------------ ------
  Age (years)                                                
   \<65                           148 (75.13)   76 (72.38)   0.60
   ≥65                            49 (24.87)    29 (27.62)   
  Gender                                                     
   Male                           125 (63.45)   71 (67.62)   0.47
   Female                         72 (36.55)    34 (32.38)   
  Histologic grade                                           
   Moderate/well differentiated   128 (64.97)   77 (73.33)   0.46
   Poorly differentiated          46 (23.35)    23 (21.90)   
  Primary site                                               
   Right                          65 (32.99)    25 (23.81)   0.14
   Left                           132 (67.01)   76 (72.38)   
  T-stage                                                    
   T1--3                          126 (63.96)   59 (56.19)   0.25
   T4                             69 (35.03)    43 (40.95)   
  Lymph node status                                          
   pN0                            53 (26.90)    39 (37.14)   0.06
   pN+                            140 (71.07)   63 (60.00)   
  MMR status                                                 
   dMMR                           5 (2.54)      9 (8.57)     0.02
   pMMR                           192 (97.46)   96 (91.43)   
  Previous therapy                                           
   De novo metastatic disease     161 (81.73)   79 (75.24)   0.18
   Previous (neo)adjuvant         36 (18.27)    26 (24.76)   
  Oligometastatic status                                     
   Yes                            80 (40.61)    55 (52.38)   0.05
   No                             117 (59.39)   50 (47.62)   
  No. of metastatic organs                                   
   1                              124 (62.94)   73 (69.52)   0.25
   ≥2                             73 (37.06)    32 (30.48)   

**Note:** *P*-values were based on *χ*^2^ or Fisher's exact test, as appropriate.

**Abbreviations:** dMMR, deficient mismatch repair; pMMR, proficient mismatch repair; TIL, tumor-infiltrating lymphocyte.

###### 

Association of TIL with prognosis (overall survival) in the whole study population

  Variable                        Univariate analysis   Multivariate analysis                        
  ------------------------------- --------------------- ----------------------- -------------------- ---------
  Age (years)                                                                                        
   \<65                           --                    0.004                   --                   0.008
   ≥65                            1.620 (1.16--2.26)                            1.60 (1.13--2.27)    
  Gender                                                                                             
   Male                           --                    0.55                                         
   Female                         1.098 (0.81--1.50)                                                 
  Histologic grade                                                                                   
   Moderate/well differentiated   --                    0.42                                         
   Poorly differentiated          1.16 (0.81--1.67)                                                  
  Primary site                                                                                       
   Right                          --                    0.045                   --                   0.37
   Left                           0.72 (0.53--0.99)                             0.85 (0.60--1.21)    
  T-stage                                                                                            
   T1--3                          --                    0.11                                         
   T4                             1.29 (0.95--1.75)                                                  
  Lymph node status                                                                                  
   pN0                            --                    0.004                   --                   0.04
   pN+                            1.67 (1.18--2.37)                             1.48 (1.02--2.13)    
  MMR status                                                                                         
   dMMR                           --                    0.10                                         
   pMMR                           1.89 (0.88--4.05)                                                  
  Previous therapy                                                                                   
   De novo metastatic disease     --                    0.15                                         
   Previous (neo)adjuvant         0.75 (0.51--1.11)                                                  
  Adjuvant chemotherapy                                                                              
   Negative                       --                    0.01                    --                   0.003
   Positive                       0.64 (0.46--0.90)                             0.58 (0.41--0.83)    
  Metastasectomy                                                                                     
   −                              --                    \<0.001                 --                   0.02
   +                              0.40 (0.26--0.63)                             0.53 (0.32--0.89)    
  Oligometastatic status                                                                             
   No                             --                    \<0.001                 --                   \<0.001
   Yes                            0.35 (0.25--0.48)                             0.479 (0.33--0.68)   
  No. of metastatic organs                                                                           
   1                              --                    0.001                   --                   0.08
   ≥2                             1.68 (1.24--2.28)                             1.34 (0.96--1.87)    
  TILs                                                                                               
   Low                            --                    0.02                    --                   0.008
   High                           0.67 (0.48--0.92)                             0.624 (0.44--0.89)   

**Note:** All statistical tests were two-sided.

**Abbreviations:** dMMR, deficient mismatch repair; HR, hazard ratio; MMR, mismatch repair; pMMR, proficient mismatch repair; TIL, tumor-infiltrating lymphocyte.
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